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Abstract
Portal hypertension (PH) is a serious consequence of several disease states 
affecting prehepatic, intrahepatic, or posthepatic portal circulation. Backpressure 
caused by PH transmits through the collaterals to form varices at various sites. 
PH also leads to hyperdynamic congestion and altered gastrointestinal mucosal 
immune response, resulting in portal hypertensive gastropathy (PHG), portal 
hypertensive enteropathy (PHE), and portal colopathy (PC). These PH associated 
phenomena may lead to torrential life-threatening bleed or chronic blood loss 
leading to debilitating chronic anemia. Endoscopy plays a pivotal role in the man-
agement of these patients both for diagnostic and therapeutic purpose. The choice 
of therapeutic strategy depends on many factors: severity of the disease, patient’s 
clinical performance, and whether it is done as an emergency or as a prophylactic 
approach. In this chapter, we evaluate the endoscopic management of patients with 
the gastrointestinal complications of PH.
Keywords: portal hypertension, esophageal varices, gastric varices,  
portal hypertensive gastropathy, gastric antral vascular ectasia,  
portal hypertensive enteropathy, portal colopathy
1. Introduction
Portal hypertension (PH) is a serious consequence of disease states affecting 
prehepatic, intrahepatic, or posthepatic portal circulation. Liver cirrhosis, which 
leads to sinusoidal hypertension, is the most frequent etiology of PH. Cirrhosis 
causes structural distortion in the liver architecture accompanied by the rise in local 
intrahepatic vasoconstrictors. Cirrhosis also causes an increase in systemic vasodila-
tion and increased cardiac output leading to increased portal blood flow. When 
portal pressure, measured as hepatic vein portal gradient (HPVG), is >10 mm of 
Hg, it leads to development of portosystemic collaterals (Figure 1). These collaterals 
arise due to recanalization of fetal vascular channels, reversal of flow within adult 
veins, and/or because of neoangiogenesis [1]. Backpressure caused by PH transmits 
through these collaterals to perforating veins and the submucosal vessels they sup-
ply, whereby varices may form.
A PH related increase in the portal vein pressure leads to hyperdynamic conges-
tion in the gastric, small intestinal, and colonic mucosa. The mucosa undergoes 
microcirculatory changes, such as submucosal angiogenesis and vascular ectasia, 
that impair its integrity and promote its susceptibility to damage. Moreover, local 
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immune mucosal defense mechanisms are impaired in PH. All these lead to portal 
hypertensive gastropathy (PHG), portal hypertensive enteropathy (PHE), and 
portal colopathy (PC) [2, 3]. This chapter focuses on the endoscopic management 
of varices, PHG, Gastric antral vascular ectasia (GAVE), PHE, and PC.
2. Esophageal varices
Esophageal varices are present in 30–40% of patients with Child A cirrhosis and 
approximately 85% of those with Child B/C cirrhosis [4]. Despite improved surveil-
lance and treatment, the rate of variceal hemorrhage (VH) continues to be 10–15% 
per year, with an 6-week mortality of 15–25% [5]. Mortality risk is particularly high 
when VH is associated with acute kidney injury (AKI) and/or concomitant bacterial 
infections [6]. Recurrent VH occurs in 60% of patients without treatment [7].
Considering the high-risk of death when VH occurs, implementing surveillance 
strategies to prevent bleeding and death should be pursued actively in patients 
with cirrhosis. Once the patient is diagnosed with cirrhosis, a periodic surveillance 
endoscopy is warranted to look for esophageal varices. Other modalities such as 
video capsule endoscopy (VCE), computed tomography (CT) scan, or Fibroscan 
have been assessed for their role in detecting esophageal varices [8, 9]. However, 
endoscopy is still regarded as the investigation of choice.
2.1 Primary prophylaxis
The risk factors of VH are the large size of varices, red signs, and the severity 
of liver disease [10]. Primary prophylaxis must be initiated in “high-risk varices” 
(Figure 2a). This includes small varices (<5 mm) with red color signs, any varix in 
Child-C patients or large varices (>5 mm) irrespective of Child-Pugh classification 
Figure 1. 
Pathophysiology of formation of varices in cirrhosis.
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[11]. In patients with “low-risk varices” or no varices, surveillance endoscopy 
should be undertaken at interval of 2–3 years, depending on the severity of the liver 
disease and whether the liver injury is ongoing or not (Figure 3). The patients with 
active alcoholism, non-alcoholic steatohepatitis (NASH), hepatitis B and C with 
detectable viral load are some examples of ongoing liver injury.
The primary prophylaxis of “high-risk varices” involves pharmacological pro-
phylaxis using a nonselective beta-adrenergic blockers (NSBB) or endoscopic band 
ligation (EVL). NSBBs such as propranolol and nadolol reduce cardiac output and 
splanchnic blood flow through nonselective beta-blockade, and the unopposed effect 
of alpha-1 adrenergic receptors leads to splanchnic vasoconstriction. This reduces 
the portal pressure and its consequential complications. Carvedilol, an NSBB with 
Figure 2. 
Endoscopic appearance of esophageal varix. (a) Large esophageal varix with red color signs, (b) esophageal 
varix after endoscopic band ligation.
Figure 3. 
Algorithm for surveillance and primary prophylaxis of esophageal varix.
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intrinsic anti-alpha-1 receptor activity, reduces both porto-collateral and intrahe-
patic resistance. However, this is at the cost of more profound effects on the systemic 
arterial pressure, particularly in decompensated patients. Carvedilol is therefore, 
preferred in patients where NSSB are contraindicated or produce side effect.
EVL (Figure 2b) involves the placement of rubber rings on variceal columns, 
which are sucked into a plastic hollow cylinder attached to the endoscope tip. 
Ligation causes occlusion of the varix and subsequent thrombosis with ischemic 
necrosis of the mucosa. Band placement should be limited to the distal 8 cm seg-
ment of the esophagus in order to target the palisade drainage and perforating 
zones. Bands should be placed helically, moving distal to proximal to allow the max-
imum number of bands to be applied while avoiding overlapping circumferential 
placement. More proximal placement has less efficacy and may cause post ligation 
retrosternal discomfort. Complications after EBL occur in approximately 2–20% of 
the patients and include transient dysphagia, retrosternal pain, esophageal stric-
ture, ulceration, perforation, and infection [12]. Occasionally, massive bleeding can 
occur, either from recurrent variceal rupture or from post-ligation ulceration.
It is generally recommended that small varices with red signs should be treated 
with NSBBs. Large varices can be treated with either NSBBs or EBL. The treatment 
choice is based on local resource and expertise, patient preference, contraindica-
tions, and adverse events [11, 13, 14].
2.2 Acute esophageal variceal hemorrhage (AVH)
Ruptured esophageal varices contributes to 70% of all the upper gastrointestinal 
(GI) bleeding episodes in patients with portal hypertension [15]. Initial treatment 
should always target restoring the euvolemic status. Restrictive blood transfusion 
strategy is adequate in most patients with GI bleed [16]. Vasoactive drug therapy 
and antibiotic prophylaxis should be initiated as soon as AVH is suspected [11]. 
After adequate resuscitation, an endoscopic evaluation should be carried out in 
patients with acute variceal bleed, in the first 12 hours after admission [13]. Table 1 
shows various modalities which can be used to treat esophageal variceal bleed.
2.3 Endoscopic variceal band ligation (EVL)
EVL is the preferred endoscopic therapy for active bleeding, as it allows greater 
bleeding control, with lower adverse events, and improves survival compared 
to endoscopic sclerotherapy (ES) which was practiced earlier [17]. In AVH, EVL 
should be preferentially targeted toward the culprit variceal column evidenced by 
the ongoing ooze or presence of stigmata of hemorrhage. However, during active 
Endoscopic Therapy
• Variceal band ligation (EVL)
• Sclero therapy/ Glue injection
• Tamponade using
 ○ SB tube
 ○Metal stents
• Argon plasma coagulation
TIPS
Table 1. 
Therapeutic options for control of acute esophageal variceal bleed.
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bleeding, banding at the gastroesophageal junction may reduce bleeding, allowing 
visualization and appropriate targeting of subsequent bands.
Despite adequate therapy with vasoactive drugs combined with EVL, up to 
10–15% of patients with variceal hemorrhage have persistent bleeding or early 
rebleeding [18]. Transjugular intrahepatic portosystemic shunts (TIPS) should be 
considered as a rescue therapy of choice in this group of patients [13]. When TIPS 
is not feasible or in case of modest rebleeding, a second endoscopic therapy with 
repeat EVL or alternate methods may be attempted, and vasoactive drugs doses 
should also be optimized.
2.4 Endoscopic sclerotherapy and glue injection
The sclerosant injection acts by precipitating inflammation and thrombosis 
of the varix. ES involves intravariceal injection of sclerosant at and just distal to 
the site of the bleeding, or perivariceal injection performed adjacent to a varix. 
Injection should be first performed at the bleeding site, followed by perivariceal 
or intravariceal injection starting from the GE junction, with proximal injections 
at 2-cm intervals, extending up to 5 cm to 6 cm from the GE junction. Sclerosants 
used include sodium tetradecyl sulfate (Food and Drug Administration approved), 
sodium morrhuate, ethanolamine oleate, polidocanol, or absolute alcohol.
A meta-analysis of 14 studies found that EVL is better than ES in terms of lower 
rates of rebleeding and complications and a higher rate of variceal eradication [19]. 
The complications related to ES occur in up to 40% of patients, and include esopha-
geal ulceration, stricture, perforation, pleural effusion, hemothorax, pulmonary 
thromboembolism, pericarditis, mediastinitis, pneumothorax, renal dysfunction, 
and even death [20]. Though EVL is the therapy of choice for the management of 
bleeding varices, there are a few indications where EVL is technically demanding, 
and ES can be utilized. This includes massive ongoing bleed when visualization is 
impaired, when adequate tissue suctioning into the cap is not possible due to scar, 
and in young children.
Glue injection have also been performed for active variceal bleeding. Overall, 
there is no definitive evidence supporting the use of cyanoacrylate injection for the 
management of bleeding varices or for VH prophylaxis. Tissue adhesive injection 
may be considered in conjunction with sclerotherapy. However, a RCT did show 
that using n-butyl cyanoacrylate and sclerosant injection in conjunction, resulted in 
lower rebleeding and mortality compared to using sclerotherapy alone [21].
2.5 Tamponade using balloons or metal stents
For persistent VH, where EVL has failed, as well as for EVL-related ulcer 
bleeding, balloon tamponade (BT) using Sengstaken-Blakemore (SB) tube and 
emergency TIPS have been advocated [13]. SB tube is associated with many compli-
cations and rebound bleeding. Performing TIPS in emergencies may not be feasible 
in many centres. Besides, there are cost issues and a definite risk of encephalopathy 
in the presence of advanced liver dysfunction [22]. Covered self-expanding metal 
stents (SEMS) with distinctive designs are used to produce an effective tamponade, 
controlling persistent variceal bleeding and ulcer bleeding following VBL [23, 24].
Initially, the Choo stent (diameter 18 mm, length 140 mm, NES − 18 − 080 − 070, 
MI Tech Co., Ltd) and the EllaBoubella-Danis stent (diameter 20 mm, length 95 mm, 
Ella-CS, Hradec Kralove, Czech Republic) were used. Despite demonstrating  
efficacy, these stent designs were not ideal for deployment and use in variceal 
bleeding; hence the SX-ELLA Danis Stent (Ella-CS, Hradec Kralove, Czech Republic) 
was designed [23]. SX_ELLA Danis Stent (Figure 4) is the most commonly used 
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stent for the treatment of persistent VH. It differs from the Choo stent and the 
EllaBoubela-Danis stent in having a balloon-style delivery system. These stents are 
made of nitinol, measuring 13.5 cm in length with a diameter of 25 mm in the shaft 
and 30 mm at the ends. The stents are placed usually over an endoscopically placed 
guidewire but can also be inserted at bedside without the need of an endoscope. The 
stent’s unique delivery system uses a gastric positioning balloon placed just distal to 
caudal end of the stent. The correct positioning of the stent in the distal half of the 
esophagus is established by inflating the gastric balloon and retracting the catheter 
assembly until the gastric balloon hits against the cardia. The stent is then released, 
and the gastric balloon is deflated, and the assembly catheter is removed [24]. These 
stents act by causing a steady mechanical compression causing an immediate tam-
ponade at the variceal bleed site. Compared to SB tube, these stents allow oral feeding 
and endoscopic assessment of rebleed.
In a meta-analysis of 12 studies, which evaluated SEMS placement for refrac-
tory esophageal variceal hemorrhage, the reported clinical success (absence of 
bleeding within 24 hours of SEMS placement) rate was 96% (95% CI, 0.90–1.00) 
and technical success (guidewire-assisted endoscopic SEMS deployment) rate was 
97% (95% CI, 0.91–1.00). Adverse events associated with the placement of SEMS 
include stent migration (28%), rebleeding (16%), and ulcer. However, there was no 
significant difference in mortality compared to balloon tamponade [25]. Removal 
of SX-ELLA Danis stent is advised within 2 weeks following stent insertion, under 
endoscopic guidance using the custom PEXElla extractor (Ella-CS) or usual foreign 
body forceps [26].
2.6 Argon plasma coagulation (APC)
APC is an electrosurgery-based, non-contact, multi-directional coagulation 
method. A high-frequency current is applied to the target tissue through an argon 
plasma jet with a constant depth of energy penetration (maximum 4 mm). APC has 
been used to coagulate the distal esophageal mucosa after eradicating esophageal 
varices by endoscopic variceal ligation to reduce the rate of variceal recurrence and 
need for rebanding. This technique is generally recommended as secondary pro-
phylaxis for esophageal variceal bleeding in those who have contraindications, are 
intolerant, or are non-compliant to NSSB [27]. A meta-analysis of four randomized 
controlled trials (RCT) compared the safety and efficacy of EVL alone, with EVL 
along with APC, for secondary prophylaxis of esophageal variceal bleeding. Across 
the 4 RCTs, combination therapy showed significantly lower variceal recurrence 
Figure 4. 
Ela stent: SX ELLA STENT. A) Stent design, B) stent in esophagus.
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rates (relative risk 0.19). There was no difference in re-bleeding or mortality. Fever 
occurred more often after combination therapy [28].
After ensuring the complete eradication of varices, APC is initiated 2 to 3 weeks 
after the last EVL session. APC is generally performed at a gas flow rate of 1.2–2 L/
min. The power setting of the APC current generator is adjusted at 50 to 70 W. The 
entire esophageal mucosa proximal to the esophageal junction is coagulated with 
APC in 2 sessions at 2-week intervals. In each session, one half of the mucosa is 
ablated thermally starting at the esophagogastric junction by retracting the probe 
proximally, while delivering thermal energy creating longitudinal parallel stripes of 
coagulated tissue.
3. Gastric varices
Gastric varices (GV) are the source of bleeding in 5–10% of patients with PH, 
second only to the esophageal variceal bleed [15]. GV is, however, relatively more 
common in non-cirrhotic portal hypertension (NCPH) and extrahepatic portal vein 
obstruction (EHPVO) occurring in 1/4th and 1/3rd of patients, respectively [20].
The GV classification system aligns with the therapeutic distinction and cat-
egorizes GV based on whether they are contiguous with esophageal varices or not, 
and as per their location in the stomach (Figure 5) [29]. Gastroesophageal varices 
(GOV) are contiguous with the esophageal varices extending either into the lesser 
curvature (GOV1) or the fundus along the greater curvature (GOV2). These varices 
share the pathophysiology of esophageal varices, arising from the left gastric vein 
and originate in the lamina propria. Isolated Gastric Varices (IGV) are distinct from 
GOV and can be located either in the cardia (IGV1) or outside of the cardia and fun-
dus, usually the antrum or pylorus (IGV2). These arise from the short and posterior 
gastric veins and originate in the submucosa.
Figure 5. 
Sarin Classifiaction of gastric varix. GOV- gastroesophageal varix, IGV- isolated gastric varix.
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Gastric variceal bleeding (Figure 6), although less common, has the predisposi-
tion to be more severe, associated with higher blood transfusion requirement, and 
increased morbidity, and mortality compared with esophageal variceal bleeding 
[30]. The probable cause for this is a large submucosal component of GV, the 
vascular structures feeding and draining the gastric varix, and, also, the lack of 
widespread expertise. Bleeding risk is significantly higher for the IGV1 (77%) and 
GOV2 (55%), than for GOV1 or ectopic varices (10%) [29]. EHPVO more com-
monly results in IGV1 varices, whereas cirrhosis related portal hypertension more 
commonly results in GOV2 varices.
3.1 Primary prophylaxis
There is limited data on the primary prophylaxis of GV bleeding. In a RCT 
with a sample size of 89 patients, endoscopic glue was found to be more effective 
than the beta-blocker therapy in preventing the first GV bleeding, the risk of not 
having bleed, being 87% vs. 62% respectively. There was a survival advantage 
also in the patients with GOV2 and IGV1. High-risk factors for first bleeding from 
GVs are variceal size >20 mm, MELD score > 16, and the presence of severe portal 
hypertensive gastropathy (PHG) [31] and these may be suitable for glue injection. 
The algorithm for the management of gastric varix, including role of primary 
prophylaxis is depicted in Figure 7.
3.2 Acute gastric variceal hemorrhage (AGVH)
Medical management of suspected gastric variceal bleeding includes airway pro-
tection, restrictive blood transfusion, vasoactive agents, antibiotics, and admission 
to the intensive care unit. Table 2 shows various modalities which can be used to 
treat GV. Endoscopic therapy is the initial treatment of choice. The methods utilized 
often depend on the local availability and experience. An algorithm for manage-
ment of GV is shown in Figure 7.
3.3 Glue injection
N-butyl-2-cyanoacrylate, is a monomer that rapidly undergoes exothermic 
polymerization upon contact with living tissues, getting transformed from liquid 
to a hard, brittle acrylic plastic. This tissue adhesive is used to treat bleeding GV. 
Figure 6. 
Endoscopic appearance of gastric varix. (a) Spurting bleeding from the gastric varix, (b) hemostasis after glue 
injection.
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For the glue injection, a therapeutic endoscope with a 3.7 mm working channel may 
be preferred for the accurate control of the injector catheter. The injection catheter 
should be primed with distilled water (DW) or normal saline (NS) (0.8–1 ml) to 
fill up the dead space. The gastroscope is placed in a retroflexed position close to the 
target varix. The suction is turned off, and the injection catheter with the needle 
still withdrawn, is advanced without variceal contact juxtaposed to the target varix. 
The needle is then pushed out directly into the varix, and glue is injected in 1 ml ali-
quots by using NS or DW solution to flush the glue into the varix. The needle should 
be immediately withdrawn after the glue injection to prevent entrapment into the 
varix. While withdrawing the needle, the flushing of a steady stream of the solution 
is aimed at the varix’s puncture site. The varix’s blunt palpation is done by catheter 
or biopsy forceps, and additional glue is injected until the varix is ‘hard’ to palpate.
Overall success in term of hemostasis is noted in 84–100% of GV treated with 
glue. Technical complications related to glue injection include needle entrapment 
in a varix, exposure to the eyes of endoscopists or the assistants, or endoscope 
damage. Clinical complications from cyanoacrylate injection occur in up to 7% of 
cases and involve systemic embolization, sepsis, gastric ulcer, rebleeding due to cast 
extrusion, and mesenteric hematoma. Embolisation can be fatal and can involve 
Figure 7. 
Algorithm for management of gastric varix. Depending the expertise available. TIPS Transjugular intrahepatic 












Therapeutic options for control of acute gastric variceal bleed.
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lung, portal vein, coronary arteries, spleen, or even brain with risk increasing more 
with excessive and forceful glue injection. Visceral fistulization from the stomach 
into the pleura or mediastinum also may occur after unintentional paravariceal glue 
injection [32].
3.4 Sclerosant injection
Injection of sclerosants like tetradecyl sulphate and alcohol is one of the oldest 
techniques endoscopists used, in order to control acute gastric variceal bleeding. 
Sclerotherapy involves injection of a combination of para- and intra-variceal injec-
tions, or 5–10 ml of intravariceal sclerosant injection into the actively bleeding GV. 
Rebleeding rate is reported to be between 10 and 20%.
On comparing glue injection versus sclerotherapy in a RCT of 37 patients 
with IGV-1, glue was more efficacious than alcohol sclerotherapy in immediate 
hemostasis (89% vs. 62%), variceal obliteration (100% vs. 44%), and achieving 
quicker variceal obliteration (2 weeks vs. 4.7 weeks) [33]. Sclerosant injection 
is associated with high rates of complications, including gastric ulceration, 
perforation, and rebleeding (37–53%), and hence, it is not a good option in the 
management of GV [34, 35].
3.5 Thrombin injection
Thrombin tissue adhesives include thrombin, a human or bovine protein that 
affects hemostasis by converting fibrinogen to a fibrin clot. Thrombin also achieves 
hemostasis by altering the platelet aggregation. Human thrombin injection gen-
erally consists of 5 ml of reconstituted solution in calcium-chloride containing 
thrombin 500 IU/ml (Floseal; Baxter Healthcare Corporation, CA, Hayward, USA). 
During each session, usually 5 mL of thrombin solution is injected in a varix.
In an only RCT available which compares thrombin to cyanoacrylate injection in the 
control of AGVH, thrombin injection and glue injection had similar success rate (90% 
vs. 90.9%). However, a higher incidence of complications (51% vs. 12%) and ulcers 
(37% vs. 0%) were noted with glue injection as compared to thrombin [36]. Results of 
this study cannot be generalized as the sample size used in this study was small.
3.6 Endoscopic ultrasound (EUS) -guided therapies
EUS can improve the endoscopic management of gastric varices in many 
regards. These include – a) Increased detection rate of gastric varices overlooked as 
gastric folds. b) Ability to use doppler to confirm variceal obliteration and predict-
ing the rebleeding risk. c) Adequate visualization of culprit gastric varix even in 
presence of torrential hemorrhage or blood clots and d) EUS-guided glue injection 
can be done precisely into a perforating vessel with preceding contrast injection to 
identify the feeding vessel as efferent or afferent, and thereby reducing emboliza-
tion risk by enabling the use of a smaller volume of glue. e) EUS provides additional 
information regarding portal vein and splenic vein patency, helping to assess 
need and feasibility candidacy for TIPS/Balloon-occluded retrograde transvenous 
obliteration (BRTO) in failed cases [37].
The technique of EUS guided glue therapy involves filling the gastric fundus 
with water to improve acoustic coupling and visualization. The EUS is then posi-
tioned either in the distal esophagus (transesophageal-transcrural approach) or in 
the cardia/fundus (transgastric approach) to visualize the intramural varices and 
feeder vessels. EUS-directed intravascular puncture of the GV is performed using a 
standard FNA needle.
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Reports have suggested that the initial deployment of intravascular coils in the 
GV provides a scaffold for glue polymerization and fixation, reducing the glue 
requirement and inadvertent glue embolization [38] (Figure 8). Various commer-
cially available coils include 0.035-inch MReye coils (extended embolus length 5 to 
10 cm, coiled embolus diameter 10 mm; IMWCE 35, Cook Medical) or Hilal micro 
coils (extended embolus length 2 cm, coiled embolus diameter 2 mm; Embolization 
micro coil, MWCE, William Cook Europe, Bjeeverskov, DK). Generally, a 5-cm 
MReye coil are used if the vessel diameter is less than 10 mm, and a 10-cm MReye 
coil is used if the vessel diameter was more than 10 mm. Once the needle is inside 
the gastric varix, stylet is withdrawn, and the coil is deployed by advancing the 
stiffer part of a 0.035-inch guidewire. After coil is deployed, 1 ml aliquots of glue is 
injected, followed by NS flush, using the same needle. Color Doppler after treat-
ment can confirm the absence of flow in the treated varix.
EUS-guided coil and cyanoacrylate injection was found to yield a 100% hemostatic 
success rate in a single-center pilot study [39]. Additionally, there were no procedure-
related complications reported [39]. A recently published meta-analysis that compared 
treatment efficacy of EUS guided glue and coil injection with the endoscopic glue injec-
tion alone reported a statistically significant benefit of variceal obliteration in the EUS 
group (86.2% vs. 62.6%). The results were however, comparable in both the groups in 
terms of treatment efficacy, recurrence of gastric varix, early and late rebleeding [40].
3.7 Hemospray
TC-325 (Hemospray, Cook Medical, Winstom-Salem, North Carolina, United 
States) is a hemostatic powder which, when in contact with blood or tissue in the 
GI tract, becomes cohesive and adhesive, and forms a physical barrier, coating the 
bleeding site. Its effect lasts approximately 24 hours because the hemostatic layer 
sloughs off. Currently, it is only licensed for the treatment of non-variceal upper GI 
bleed. However, two recent studies demonstrated that Hemospray could be used as 
a bridge to a definitive treatment in active variceal bleeding [41, 42].
4. Ectopic varices
Ectopic varices (EcV) have a very complex anatomy. Understanding anastomosis 
with the splanchnic venous system is essential in managing EcV. These are rare 
Figure 8. 
Endosonographic coil embolization of the gastric varix. (a)Endosonography view of gastric varix (blue arrow) 




Hemobilia due to choledochal varix and its treatment with metal stent. (a) Endoscopic appearance at side 
viewing examination showing spurting from papilla due to choledochal varix, (b) after deployment of covered 
self-expanding metal stent.
cause of bleeding in patients with cirrhosis and PH, accounting for only 2–5% cases 
[43]. They are more common in patients with prehepatic PH, occurring in 27–40% 
of patients with splanchnic vein thrombosis [44]. However, EcV bleed is more 
severe than esophageal variceal bleeding, with mortality rates up to 37.5% [45]. 
Ectopic varix can develop in the duodenum, small bowel, rectum, colon, gallblad-
der, and biliary tract, periumbilical, peristomal, and the retroperitoneal areas. 
Endoscopy is used for both diagnosis and therapy. Most of the EcV are within reach 
of standard EGD and colonoscopy. A bleeding small intestinal varix may occasion-
ally require the use of capsule endoscopy and device-assisted enteroscopy.
The treatment of bleeding of EcV is extrapolated from the esophageal and 
gastric varices literature. Successful outcomes depend on local expertise, location 
of varices, and the technical feasibility. ES and glue injection are commonly used 
modalities. EVL can be used to manage the rectal and duodenal varix. Caution 
however, must be exercised if the varix size is bigger, as the chances of hemostasis 
are less and the risk of rebleeding is high. Use of APC with EBL may be considered 
for the prevention of variceal occurrence, as has been reported in the treatment of 
ileocolonic anastomotic varices [45]. Hemostatic clip placement has been reported 
for ectopic variceal therapy [46]. Hemobilia, due to choledochal varices, can be life-
threatening. Placement of a covered biliary metal stent (Figure 9a, b) is a promis-
ing approach to achieve immediate hemostasis for bleeding from portal biliopathy 
and associated choledochal varix. Biliary stenting serves as salvage therapy and a 
bridge to elective devascularization and shunt surgery [47].
5. Portal hypertensive gastropathy (PHG)
PHG, typically seen in patients with PH, is a condition of gastric mucosal 
ectasia and impaired mucosal defense. The incidence of PHG in patients with 
PH, varies greatly, ranging between 20 and 75%. Of those approximately 65–90% 
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have mild PHG (mosaic pattern of the gastric mucosa without red spots), whereas 
10–25% have severe PHG (mosaic pattern of the gastric mucosa with red spots; 
Figure 10) [48]. The ectatic mucosal capillaries and venules of PHG may cause 
recurrent bleeding, presenting as acute or chronic occult blood loss. The annual 
incidence of overt bleeding from mild PHG is about 5%, while it is 15% for severe 
PHG [49]. The frequency of rebleeding of PHG is 11–30% [50].
APC has been evaluated for the treatment of PHG, in combination with adequate 
NSBB. This does reduce rates of blood transfusion, ICU admission, and improve 
hemoglobin levels in 80–90% of patients [51, 52]. Hemospray is also an option for 
the treatment of active PHG bleeding. However, these endoscopic methods may be 
an effective bridging therapy till TIPS or liver transplant is performed [53].
6. Gastric antral vascular ectasia (GAVE)
GAVE is characterized by erythematous or raised mucosa with underlying tortu-
ous ectatic vessels as red spots. Patterns of GAVE include honeycombing, diffuse 
or speckled patchy erythema, and nodular antral GAVE. These appear as diffuse or 
linear array in the gastric antrum (Figure 11a). Both PHG and GAVE may be found 
during endoscopy in patients with PH or discovered during variceal screening. 
However, in most instances, they are distinguished by their endoscopic appearance, 
location and when needed, biopsy for histological examination. (Table 3). On histol-
ogy, GAVE shows presence of fibromuscular hyperplasia, fibrin microthrombi, and 
increased neuroendocrine cells in the lamina propria [54]. GAVE can be isolated or 
can be associated with cirrhosis and with systemic illnesses like scleroderma, chronic 
renal failure, and can occur after bone marrow transplantation. PH does not play a 
direct role in development of GAVE, as it is not present in up to 70% of patients, and 
the reduction of portal hypertension does not affect the course of the disease [55].
The endoscopic treatment includes laser photoablation, APC, radio-frequency 
ablation [56], EVL, and cryotherapy. APC is the most common, efficacious, 
and feasible therapeutic option for the treatment of GAVE (Figure 11b), with 
a reported efficacy of 90%- 100% causing a significant reduction in blood 
Figure 10 





Gastric Antral Vascular 
Ectasia
1. Definition PHG, typically seen in 
patients with PH, is a 
condition of gastric mucosal 
ectasia and impaired 
mucosal defense
It is characterized by 
erythematous or raised 
mucosa with underlying 
tortuous ectatic vessels 
as red spots in either a 
diffuse or linear array
2. Location Gastric fundus and body Gastric antrum
3. Association with Portal 
HTN
Always In approximately 30% 
case
4. Histology Dliated mucosal and 
submucosal veins along 
with ectatic capillaries 






cells in the lamina propria
5. Endoscopy Mosaic pattern (mild) with 
red spots (severe)
Honeycombing, Diffuse 
or speckled patchy 
erythema, and nodular 
antral lesions
6. Incidence of bleed Low Higher than PHG related 
bleed










Difference between portal hypertensive Gastropathy and gastric antral vascular ectasia.
transfusion requirement [57, 58]. The setting of argon gas flow usually ranges 
between 0.8–2.0 L/min, the electrical power from 40 to 60 W, and, generally, a 
mean of 2.5 sessions are needed to achieve complete eradication [59]. Few studies 
have compared EVL with APC for GAVE treatment, where band ligation showed a 
Figure 11. 
Endoscopic appearance of gastric antral vascular ectasia. (a) Endoscopic appearance of gastric antral vascular 
ectasia, (b) appearance after argon plasma coagulation.
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significantly higher rate of hemostasis, required fewer treatment sessions, a higher 
increase in hemoglobin values, and reduced need for blood transfusions [60, 61]. 
The higher efficacy EVL is attributed to a more controlled and reliable eradication 
of the abnormal vasculature in the mucosa and submucosa.
7. Portal hypertensive enteropathy (PHE)
PHE is a condition associated with pathologic changes and mucosal abnormali-
ties in the small intestine of patients with PH. It is being increasingly diagnosed, 
due to the advent of video capsule endoscopy and deep enteroscopy. In recent stud-
ies, the prevalence of PHE varies around 93–97%, with 8–12% of patients showing 
evidence of ongoing bleeding [62–64]. The findings of PHE are characterized as 
vascular (red spots, telangiectasia, or varices) and non-vascular or inflammatory 
(villous edema, erythema, or polyps) changes [64] (Figure 12a-f).
Treatment options for PHE related bleed include glue or sclerosant for variceal 
bleeding and APC for non-variceal bleeding. In patients with hemodynamic insta-
bility, radiological coil embolization is an option [64].
8. Portal hypertensive COLOPATHY (PHC)
Colonic abnormalities in patients with PH are referred to as PHC, and these are 
vascular ectasias, mosaic pattern mucosa, mucosal hemorrhages, anorectal or colonic 
varices, hemorrhoids, and nonspecific inflammatory changes. Its prevalence in 
patients with cirrhosis varies from 25 to 70%, with an estimated bleeding rate of 0–9% 
Figure 12. 
Capsule endoscopy appearance of portal hypertensive enteropathy. a-c: Vascular: (a) red spot, (b) 
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[65–68]. Treatment options are ES or glue injection for variceal bleed, EVL for hemor-
rhoidal bleed, and APC for the non-variceal bleed and are similar to those in PHE.
9. Summary
PH can result in formation of varices at various sites with mucosal changes 
anywhere in the gastrointestinal tract. These can lead to acute gastrointestinal bleed 
or anemia. Endoscopy plays an important role in diagnosis and treatment of these 
complications. EVL and glue are the usual first line treatment for esophageal and 
GV respectively. Other therapies include sclerosant or thrombin injection, EUS-
guided therapies, esophageal stent placement, APC or hemospray.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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